title: Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patients.
abstract: BACKGROUND
  The agents etoposide and carboplatin are active against ovarian cancer and display synergistic anti-tumor activity in animal tumor models. The objective of these two phase II trials was to determine the efficacy and toxicity of the combination of etoposide with carboplatin in previously treated and untreated patients with ovarian cancer.
  
  
  METHODS
  Etoposide (100 mg/m2) was administered as a one-hour infusion on three consecutive days and carboplatin (400 mg/m2) as a 30-minute infusion on day 2 of each monthly scheduled cycle. In 20 patients, previously treated with cisplatin-containing regimens, a total of 102 cycles was applied as salvage therapy (ST) and in 27 patients, a total of 168 cycles as first-line therapy (FLT).
  
  
  RESULTS
  ST yielded 2 complete remissions (CR) and one partial remission (PR); in 7 patients, no evidence of disease (NED) and in 6 patients, no change (NC) were observed. The progression-free intervals (PFI) lasted a median 7.0 months (range < 2-14 months). FLT resulted in 7 CR (4 of them pathologically (p) verified), 11 NED (1 pNED), 3 PR (1 pPR) and 6 NC. The objective response rate was 63% (95% confidence interval: 36-89%). PFI lasted a median 8.0 months (range 3-25+ months); median survival had not been reached at the time of evaluation. Thrombocytopenia (WHO grade 4) was the limiting toxicity.
  
  
  CONCLUSIONS
  Although not fulfilling the expectations of synergistic activity as shown in preclinical models, the combination of etoposide with carboplatin is an active and feasible therapy regimen in the out-patient management of ovarian cancer.
authors.affiliation: Department of Internal Medicine I, University of Vienna, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Dittrich
authors.forename: M
authors.initials: M
authors.lastname: Baur
authors.forename: N
authors.initials: N
authors.lastname: Vavra
authors.forename: M
authors.initials: M
authors.lastname: Hudec
authors.forename: B
authors.initials: B
authors.lastname: Fazeny
authors.forename: M
authors.initials: M
authors.lastname: Barrada
authors.forename: H
authors.initials: H
authors.lastname: Salzer
authors.forename: P
authors.initials: P
authors.lastname: Sevelda
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D016879:Salvage Therapy; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D005047:Etoposide; D016190:Carboplatin